ValuEngine Upgrades Bristol-Myers Squibb (BMY) to “Hold”

Share on StockTwits

ValuEngine upgraded shares of Bristol-Myers Squibb (NYSE:BMY) from a sell rating to a hold rating in a research report report published on Friday.

A number of other equities analysts have also weighed in on BMY. Societe Generale set a $47.00 target price on Bristol-Myers Squibb and gave the stock a sell rating in a research note on Wednesday, November 14th. BMO Capital Markets increased their target price on Bristol-Myers Squibb from $55.00 to $58.00 and gave the stock a market perform rating in a research note on Friday, November 16th. William Blair reiterated an outperform rating on shares of Bristol-Myers Squibb in a research note on Tuesday, November 27th. Morgan Stanley lowered their target price on Bristol-Myers Squibb from $63.00 to $59.00 and set a hold rating on the stock in a research note on Tuesday, November 6th. Finally, Credit Suisse Group set a $61.00 target price on Bristol-Myers Squibb and gave the stock a hold rating in a research note on Sunday, October 14th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and eight have assigned a buy rating to the stock. Bristol-Myers Squibb presently has an average rating of Hold and a consensus target price of $61.95.

Shares of NYSE BMY traded down $0.17 during trading hours on Friday, reaching $53.08. 9,402,802 shares of the stock were exchanged, compared to its average volume of 7,962,205. The firm has a market cap of $86.91 billion, a P/E ratio of 17.63, a price-to-earnings-growth ratio of 1.48 and a beta of 1.11. The company has a current ratio of 1.53, a quick ratio of 1.40 and a debt-to-equity ratio of 0.41. Bristol-Myers Squibb has a 52 week low of $46.94 and a 52 week high of $70.05.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, October 25th. The biopharmaceutical company reported $1.09 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.91 by $0.18. The company had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.72 billion. Bristol-Myers Squibb had a return on equity of 47.89% and a net margin of 6.50%. Analysts forecast that Bristol-Myers Squibb will post 3.87 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 1st. Shareholders of record on Friday, January 4th will be paid a dividend of $0.41 per share. This represents a $1.64 dividend on an annualized basis and a yield of 3.09%. The ex-dividend date of this dividend is Thursday, January 3rd. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.40. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 53.16%.

A number of institutional investors have recently bought and sold shares of BMY. Wealth Architects LLC boosted its holdings in shares of Bristol-Myers Squibb by 14.0% in the 3rd quarter. Wealth Architects LLC now owns 6,923 shares of the biopharmaceutical company’s stock valued at $430,000 after purchasing an additional 848 shares in the last quarter. Beech Hill Advisors Inc. boosted its holdings in shares of Bristol-Myers Squibb by 0.8% in the 3rd quarter. Beech Hill Advisors Inc. now owns 105,500 shares of the biopharmaceutical company’s stock valued at $6,549,000 after purchasing an additional 850 shares in the last quarter. Signature Financial Management Inc. boosted its holdings in shares of Bristol-Myers Squibb by 1.9% in the 2nd quarter. Signature Financial Management Inc. now owns 46,006 shares of the biopharmaceutical company’s stock valued at $2,546,000 after purchasing an additional 870 shares in the last quarter. Mcmillion Capital Management Inc. boosted its holdings in shares of Bristol-Myers Squibb by 1.4% in the 2nd quarter. Mcmillion Capital Management Inc. now owns 64,044 shares of the biopharmaceutical company’s stock valued at $3,544,000 after purchasing an additional 903 shares in the last quarter. Finally, Securian Asset Management Inc boosted its holdings in shares of Bristol-Myers Squibb by 0.5% in the 2nd quarter. Securian Asset Management Inc now owns 167,108 shares of the biopharmaceutical company’s stock valued at $9,248,000 after purchasing an additional 912 shares in the last quarter. Hedge funds and other institutional investors own 72.74% of the company’s stock.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.

Featured Story: Calculate Your Return on Investment (ROI)

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.